Detalles de la búsqueda
1.
Early Ultrasound Response and Progressive Transmural Remission After Treatment With Ustekinumab in Crohn's Disease.
Clin Gastroenterol Hepatol
; 21(1): 153-163.e12, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35842121
2.
Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial.
Clin Gastroenterol Hepatol
; 20(12): 2858-2867.e5, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35276329
3.
Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS).
Int J Clin Pract
; 71(10)2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28851109
4.
Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST.
Aliment Pharmacol Ther
; 59(2): 175-185, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38036946
5.
Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trial.
United European Gastroenterol J
; 11(5): 410-422, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37139642
6.
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
Lancet Gastroenterol Hepatol
; 7(4): 294-306, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35120656
7.
Multicenter, open-label, nonrandomized, observational safety study in subjects using insulin aspart in basal-bolus regimen for the treatment of diabetes.
Pol Arch Med Wewn
; 120(11): 444-50, 2010 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-21102380
Resultados
1 -
7
de 7
1
Próxima >
>>